Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026

Summary

Insmed will present data from its respiratory portfolio at the European Respiratory Society Congress 2026, including late-breaking Phase 3b ENCORE study results for ARIKAYCE and new data on BRINSUPRI in non-cystic fibrosis bronchiectasis patients with nontuberculous mycobacterial lung disease history.